Opinion
Video
Panelists discuss how treatment success in immunoglobulin A (IgA) nephropathy extends beyond clinical trial end points to encompass sustained proteinuria reduction, stable kidney function, symptom improvement, and enhanced quality of life metrics that matter to patients in real-world settings.
Measuring Treatment Success in IgA Nephropathy: Beyond Clinical Trial End Points
Practical Markers of Treatment Response
Short-term Indicators (3-6 Months)
Intermediate Indicators (6-24 Months)
Long-term Success Metrics
Practical Monitoring Approach
Limitations of Current Approaches
Integrating these practical measures into routine care allows for more nuanced assessment of treatment success and timely intervention when therapy adjustments are needed.
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.